|Articles|September 9, 2022
- Pharmaceutical Executive-09-01-2022
- Volume 42
- Issue 9
Pharmaceutical Executive, September 2022 Issue (PDF)
Advertisement
Articles in this issue
almost 4 years ago
ESG: Applying Lessons From Consumer Marketalmost 4 years ago
21st Annual Industry Audit: Pharma Performance Checkalmost 4 years ago
DE&I in Pharma Sales & Marketing: ‘While There’s Work, There’s Promise’almost 4 years ago
The Manufacturing Edge on Path to Marketalmost 4 years ago
How Good is a Good Product Launch?almost 4 years ago
More Than a Name: Vyvgartalmost 4 years ago
Fighting Vision Loss: Vabysmoalmost 4 years ago
A Sleeping Giant?: Quviviqalmost 4 years ago
Next-level Efficacy: MounjaroAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
5